
- /
- Supported exchanges
- / US
- / SMDPY.PINK
Sumitomo Pharma Co. Ltd (SMDPY PINK) stock market data APIs
Sumitomo Pharma Co. Ltd Financial Data Overview
Sumitomo Pharma Co., Ltd. engages in manufacture, purchase, and sale of pharmaceutical products for medical treatment in Japan, North America, and Asia. The company offers therapeutic agents for parkinson's disease, type 2 diabetes, advanced prostate cancer, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. It also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, the company offers veterinary drugs, medical devices, etc. It has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Sumitomo Pharma Co. Ltd data using free add-ons & libraries
Get Sumitomo Pharma Co. Ltd Fundamental Data
Sumitomo Pharma Co. Ltd Fundamental data includes:
- Net Revenue: 416 159 M
- EBITDA: 61 013 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-29
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Sumitomo Pharma Co. Ltd News

Sumitomo Pharma (TSE:4506) — Assessing Valuation After a 238% Year-to-Date Share Price Surge
Sumitomo Pharma (TSE:4506) shares have been on the move recently, and investors are looking at the stock’s performance amid shifting market conditions. Short-term gains and longer-term returns are b...


Knight Therapeutics Announces Relaunch of ORGOVYX® in Canada
Knight Therapeutics MONTREAL, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has r...

Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada
Knight Therapeutics MONTREAL, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that it h...

Trump’s overnight demand for 100% tariffs on pharmaceuticals will be ‘a meaningful commercial hit for U.S. consumers,’ top analyst says
President Trump’s 100% tariff on imported branded pharmaceuticals is expected to hit American consumers and global drug stocks, but there are loopholes: Generic drugs are excluded, and there are exe...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.